SCHEMBL16570901

SCHEMBL16570901

FC(F)Oc1ccccc1Cn1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 11/20 0.63
▸ CDK4 P11802 6/20 0.49
▸ CCND1 P24385 4/20 0.49
▸ CDK2 P24941 4/20 0.49
▸ CCNA2 P20248 3/20 0.49
▸ JAK2 O60674 3/20 0.46
▸ BRD4 O60885 3/20 0.46
▸ JAK1 P23458 2/20 0.46
▸ BRD2 P25440 2/20 0.46
▸ JAK3 P52333 2/20 0.46
▸ BRD3 Q15059 2/20 0.46
▸ BRDT Q58F21 2/20 0.46
▸ CCNE1 P24864 2/20 0.45
▸ FGFR1 P11362 2/20 0.45
▸ FGFR2 P21802 2/20 0.45
▸ FGFR4 P22455 2/20 0.45
▸ FGFR3 P22607 2/20 0.45
▸ CCNE2 O96020 1/20 0.45
▸ CCND2 P30279 1/20 0.45
▸ CCND3 P30281 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17958820 0.89 STAT6 (0.54) STAT6CDK4CCND1JAK3FGFR1
SCHEMBL16581003 0.89 STAT6 (0.54) STAT6CDK4CCND1JAK3FGFR1
SCHEMBL16580815 0.88 STAT6 (0.61) STAT6CDK4CCND1CDK2CCNA2
SCHEMBL16571340 0.80 STAT6 (0.62) STAT6CDK4CCND1CDK2CCNA2
SCHEMBL16580900 0.80 STAT6 (0.48) STAT6CDK2JAK2JAK1JAK3
SCHEMBL16570197 0.80 STAT6 (0.64) STAT6CDK4CCND1CDK2CCNA2
SCHEMBL16570305 0.80 STAT6 (0.48) STAT6CDK2JAK2JAK1JAK3
SCHEMBL16580806 0.80 FGFR4 (0.66) JAK2BRD4JAK1BRD2JAK3
SCHEMBL16580932 0.80 STAT6 (0.59) STAT6CDK4CCND1CDK2CCNA2
SCHEMBL16580898 0.80 STAT6 (0.59) STAT6CDK4CCND1CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN STAT6 103/4885CDK4 243/4885CCND1 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback